Sign in

    Ben Clevenger

    Managing Director and Senior Equity Research Analyst at Truist Securities

    Ben Clevenger is a Managing Director and Senior Equity Research Analyst at Truist Securities, specializing in coverage of the healthcare and life sciences sector, with a particular focus on medical technology and diagnostics companies. He covers leading firms such as Abbott Laboratories, Boston Scientific, and Medtronic, demonstrating a strong performance track record as evidenced by high rankings on industry platforms and consistent positive returns on covered stocks. Clevenger began his finance career in the early 2000s, holding analyst positions at Raymond James and JP Morgan before joining Truist Securities in 2017. He holds FINRA Series 7, 63, and 86/87 licenses, reflecting his professional credentials in equity research and securities analysis.

    Ben Clevenger's questions to GLOBUS MEDICAL (GMED) leadership

    Ben Clevenger's questions to GLOBUS MEDICAL (GMED) leadership • Q4 2024

    Question

    Ben Clevenger, on for Richard Newitter at Truist Securities, asked about the key considerations that could drive results to the high or low end of the 2025 EPS guidance range that includes the Nevro acquisition. He also inquired about potential tariff exposure.

    Answer

    CFO Keith Pfeil explained that the EPS range for the combined company will be influenced by sales performance and the ability to control the cost structure of the acquired Nevro business. Regarding tariffs, Pfeil and CEO Dan Scavilla stated that exposure is 'extremely immaterial,' as approximately 95% of products are U.S.-based or sourced, with the remainder being mostly long-term instrumentation.

    Ask Fintool Equity Research AI